Trial: 202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T
cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and
Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in
Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Phase

III

Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov